---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-26-000002"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:47:45.145917+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amphastar Licenses Synthetic Corticotropin (AMP-110) from Hanxin in Exclusive US/Canada Deal

## Summary
- Amphastar gained exclusive rights to develop and commercialize AMP-110 (synthetic ACTH) in the US and Canada from Nanjing Hanxin.
- Upfront payment of $2 million; potential milestones up to $14 million (development) and $75 million (sales).
- Royalty payments capped at $7.5 million per year and $60 million total; Hanxin will also pay Amphastar royalties on certain sales.
- Related-party transaction: CEO Jack Zhang and Chairman Mary Luo beneficially own a majority of Hanxin.
- US ACTH market exceeded $684 million in 2024; AMP-110 aims for inflammatory and autoimmune conditions.

## SEC filing metadata
- accession: 0001297184-26-000002
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000002/0001297184-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000002/amph-20260106x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-26-000002
- JSON: https://secwatch.observer/filing/0001297184-26-000002.json
- Plain text: https://secwatch.observer/filing/0001297184-26-000002.txt

## Key facts
- Material Agreements
  Amphastar Pharmaceuticals, Inc. amended Manufacturing Amendment with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at Change in value not determinable; expands territory globally except US and Canada for Lidocaine and (effective 2026-01-06).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
  - Value: Change in value not determinable; expands territory globally except US and Canada for Lidocaine and
  - Effective: 2026-01-06
  source text: On January 6, 2026, Amphastar Nanjing Pharmaceuticals, Inc., the Chinese subsidiary of Amphastar and Hanxin entered into an amendment to the Manufacturing Agreement (the “Manufacturing Amendment”), originally entered into on April 19, 2022, as previously reported by the Company on a Current Report on Form 8-K filed on April 22, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000002/0001297184-26-000002-index.htm
- Material Agreements
  Amphastar Pharmaceuticals, Inc. entered into License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. valued at Amphastar made an upfront payment of $2 million; development milestone payments up to $14 million; s (effective 2026-01-06).
  - Action: entry
  - Agreement: license
  - Counterparty: Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
  - Value: Amphastar made an upfront payment of $2 million; development milestone payments up to $14 million; s
  - Effective: 2026-01-06
  source text: On January 6, 2026, Amphastar Pharmaceuticals, Inc (“Amphastar” or, the “Company”), and Nanjing Hanxin Pharmaceutical Technology Co., Ltd. (“Hanxin”), entered into a License Agreement (“License Agreement”) pursuant to which Hanxin is granting an exclusive license to certain intellectual property controlled by Hanxin to develop, make, use and commercialize products incorporating or comprising of corticotropin compound (“Licensed Product”) in the United States and Canada (the “Territory”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000002/0001297184-26-000002-index.htm
- Material Agreements
  Amphastar Pharmaceuticals, Inc. amended Distribution Amendment with Hong Kong Genreach Limited valued at Change in value not determinable; expands region with additions of Middle East and Southeast Asian c (effective 2026-01-06).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Hong Kong Genreach Limited
  - Value: Change in value not determinable; expands region with additions of Middle East and Southeast Asian c
  - Effective: 2026-01-06
  source text: On January 6, 2026, Armstrong Pharmaceuticals, Inc. a wholly-owned subsidiary of the Amphastar and Hong Kong Genreach Limited (“Genreach”) a wholly-owned subsidiary of Hanxin entered into an amendment to the Distribution Agreement (the “Distribution Amendment”), originally entered into on August 28, 2024, as previously reported by the Company on a Current Report on Form 8-K filed on August 30, 2024 (the “Distribution Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718426000002/0001297184-26-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.